Rafarma Pharmaceuticals

43 articles about Rafarma Pharmaceuticals

• Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University

  12/11/2023

  Rafarma Pharmaceuticals - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023.

• Rafarma Pharmaceutical news update

  11/30/2023

  Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards.

• BNS and RAFARM create BNS Ophthalmics to leverage nanotechnology in the development of novel ophthalmic products

  5/30/2023

  RAFARM and BioNanoSim, an Israeli-based nanotechnology drug discovery and development company co-founded by Prof. Simon Benita and Yissum, the Transfer Technology and IP company of The Hebrew University of Jerusalem, have entered into an agreement to create a new Ophthalmic company called BNS Ophthalmics.

• Rafarma Pharmaceuticals strengthens its position in Central Asia

  4/29/2022

  Representatives of Rafarma Pharmaceuticals, Inc. visited Uzbekistan and discussed the prospects for the company's development in the territory of the innovative research and production pharmaceutical cluster "Tashkent Pharma Park".

• 

  Global Roundup: Celltrion Prepares to Trap COVID-19 in Phase III

  2/10/2022

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

• Rafarma’s Slavich Noya Technology Division Expands Printing Production

  2/7/2022

  Rafarma Pharmaceuticals, Inc. is expanding its production capabilities as it is in active negotiations for the acquisition of two machines from BOBST, one of the world’s leading suppliers of substrate processing, printing and converting equipment and services for the label, flexible packaging, folding carton and corrugated board industries.

• RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear Research

  12/21/2021

  Rafarma Pharmaceuticals, Inc. OTC: is currently negotiating with the Joint Institute for Nuclear Research, an international intergovernmental scientific organization established by eleven founding countries in 1956 and registered by the United Nations.

• RAFA To Add Major Component to the Tashkent Pharma Park

  12/17/2021

  Rafarma Pharmaceuticals, Inc. OTC:(RAFA) and the Czech company “Block” signed an agreement on the implementation of the construction of a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park in Uzbekistan.

• Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5

  11/19/2021

  Rafarma Pharmaceuticals, Inc. OTC: reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019.

• Rafarma Enters Negotiations With Leading Global Producer of Precious Metals to Localize Production of Platinum-Based Cancer Drugs

  8/19/2021

  Rafarma Pharmaceuticals, Inc.OTC:(RAFA) and one of the world's largest producers of precious metals, Krastsvetmet (Russia, Krasnoyarsk), discussed implementing a joint project to produce the most popular platinum-based chemotherapy drugs.

• Rafarma’s Global Pharmaceutical Strategy At A Glance

  5/18/2021

  Rafarma Pharmaceuticals, Inc. OTC: is an international biotechnological and pharmaceutical company that combines research centers and modern pharmaceutical production that meets international GMP standards.

• Rafarma To Expand Proton Therapy Centers

  5/7/2021

  Rafarma Pharmaceuticals, Inc.OTC: is pleased to announce that RAFA is in active meetings the City Scientific University of Istanbul to establish a nuclear medicine and proton therapy center at the university.

• Rafarma and Haifa Technopark Enter Talks for Joint Venture

  4/30/2021

  Rafarma Pharmaceuticals, Inc.OTC: is pleased to announce that on April 26, 2021 the company entered negotiations and formed an action plan with the Matam Technopark in Haifa, Israel to pursue joint development, acquisition and adaptation of pharmaceutical technologies.

• Rafarma Embarks on Aggressive Global Partnerships Plan

  3/4/2021

  Rafarma Pharmaceuticals, Inc.OTC: is pleased to announce its newly formulated strategies for aggressive global growth in 2021/2022.

• Rafarma Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of Uzbekistan

  1/29/2021

  Rafarma Pharmaceuticals, Inc. OTC: is pleased to announce its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan which is essentially the Health Department of Uzbekistan.

• Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer

  12/9/2020

  Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that one of the acquisition companies of the previously-announced Biocogency merger, Bebig LLC ( http://en.bebig.ru ), received an updated Russian registration certificate for the production and sale of nanostructured microspheres based on yttrium-90, used in the treatment of both primary and metastatic liver lesions. This will start industrial production and sale of ready-made

• Letter To Shareholders from Chairman Ilya Shpurov

  11/9/2020

  November 9, 2020 Rafarma Pharmaceuticals, Inc. OTC: shares the following letter to shareholders from Chairman Ilya Shpurov

• Auditing Firm L J Soldinger Associates Retained for Rafarma Biocogency Merger

  11/4/2020

  Rafarma Pharmaceuticals, Inc. OTC: is pleased to announce that the elite Chicago auditing firm LJ Soldinger Associates has been retained to provide auditing services for the resulting Rafarma group of companies from the Biocogency/Rafarma merger.

• Rafarma Closes Biocogency Merger

  10/19/2020

  Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES. The new consolidated financials will include Slavich ( http://www.slavich.ru ), Slavich Trading House and related companies based in Spain, Ireland and Cyprus, with Kras Pharma ( http://kraspharma.ru ) and Bebig ( http://en.bebig.ru /) being added in due course. The company’s Slovenian assets will be divested, p

• Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya Shpurov

  10/6/2020

  Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce approval of Ilya Shpurov receiving the majority of Preferred B shares, conferring voting control of the company, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group of Companies. The issuance of restricted preferred shares does not create any dilution of common shares. Vladimir Dolgolenko, CEO of Rafarma, commented: “we look forward to t